Oncology — API & Bulk Drug Suppliers in India

Oncology API (EGFR inhibitor). Prescription product — documentation required.

CYP17 inhibitor — tablet formulations for metastatic castration-resistant prostate cancer.

irreversible ErbB family blocker — tablet formulations for EGFR-mutated non-small cell lung cancer.

aromatase inhibitor — tablet formulations for hormone receptor-positive breast cancer in postmenopausal women.

glycopeptide cytotoxic antibiotic — injection formulations for lymphomas and germ cell tumours.

oral fluoropyrimidine prodrug — tablet formulations for colorectal, breast and gastric cancer.

second-generation BCR-ABL inhibitor — tablet formulations for chronic myeloid leukaemia and Ph+ ALL.

EGFR tyrosine kinase inhibitor — tablet formulations for non-small cell lung cancer and pancreatic cancer.

steroidal aromatase inactivator — tablet formulations for postmenopausal breast cancer.

recombinant G-CSF — injection formulations for neutropenia and stem-cell mobilisation.

LHRH agonist — implant formulations for prostate and breast cancer.

5-HT3 antagonist antiemetic — injection and tablet formulations for chemotherapy-induced nausea.

first-generation BCR-ABL inhibitor — tablet formulations for chronic myeloid leukaemia and GIST.

epothilone microtubule inhibitor — injection formulations for metastatic breast cancer.

immunomodulatory imide drug — capsule formulations for multiple myeloma and myelodysplastic syndromes.

multikinase inhibitor — capsule formulations for thyroid and hepatocellular carcinoma.

non-steroidal aromatase inhibitor — tablet formulations for postmenopausal breast cancer.

nitrogen mustard alkylating agent — tablet and injection formulations for multiple myeloma and transplant conditioning.

antifolate antimetabolite — tablet and injection formulations across oncology, rheumatology and dermatology.

antifolate antimetabolite — injection formulations for non-small cell lung cancer and mesothelioma.

CXCR4 antagonist for stem-cell mobilisation — injection formulations supporting autologous transplant collection.

hydrazine alkylating agent — capsule formulations for Hodgkin lymphoma and brain tumours.

multikinase inhibitor — tablet formulations for hepatocellular and renal cell carcinoma.

selective estrogen receptor modulator — tablet formulations for hormone receptor-positive breast cancer.

anti-HER2 monoclonal antibody — injection formulations for HER2-positive breast and gastric cancer.

non-steroidal antiandrogen — tablet formulations for prostate cancer with GnRH therapy.

platinum chemotherapy agent — injection formulations for ovarian and lung cancer.

taxane antimicrotubule agent — injection concentrate for breast, lung and prostate cancer.

anthracycline cytotoxic antibiotic — injection formulations for solid tumours and leukaemias.

nucleoside-analogue antimetabolite — injection formulations for pancreatic, lung and breast cancer.

topoisomerase I inhibitor — injection formulations for colorectal cancer.

taxane antimicrotubule agent — injection formulations for ovarian, breast and lung cancer.

multi-target tyrosine-kinase inhibitor — capsule formulations for renal cell carcinoma and GIST.

JAK1/2 inhibitor — tablet formulations for rheumatoid arthritis and atopic dermatitis.

proteasome inhibitor — injection formulations for multiple myeloma and mantle-cell lymphoma.

nitrogen-mustard alkylating agent — tablet and injection formulations for haematologic and solid malignancies.

nucleoside-analogue antimetabolite — injection formulations for acute leukaemias.

androgen-receptor signalling inhibitor — tablet formulations for castration-resistant prostate cancer.

topoisomerase II inhibitor — capsule and injection formulations for lung cancer, lymphoma and germ-cell tumours.

mTOR inhibitor — tablet formulations for renal, breast and neuroendocrine tumours, and transplant immunosuppression.

antimetabolite fluoropyrimidine — injection and topical formulations for solid tumours and actinic keratosis.

Bruton tyrosine-kinase inhibitor — capsule and tablet formulations for B-cell malignancies.

oxazaphosphorine alkylating agent — injection formulations with mesna cover for sarcomas and testicular cancer.

BCR-ABL tyrosine-kinase inhibitor — capsule formulations for chronic myeloid leukaemia.

third-generation EGFR inhibitor — tablet formulations for EGFR-mutated non-small-cell lung cancer.

CDK4/6 inhibitor — capsule and tablet formulations with endocrine therapy for HR-positive breast cancer.

multi-target tyrosine-kinase inhibitor — tablet formulations for renal cell carcinoma and soft-tissue sarcoma.

multi-kinase inhibitor — tablet formulations for colorectal cancer and GIST after prior therapy.

JAK1/2 inhibitor — tablet formulations for myelofibrosis and polycythaemia vera.

imidotetrazine alkylating agent — capsule formulations for glioblastoma and astrocytoma.

topoisomerase I inhibitor — injection and capsule formulations for ovarian, lung and cervical cancer.

BCL-2 inhibitor — tablet formulations for chronic lymphocytic leukaemia and acute myeloid leukaemia.

vinca alkaloid antimicrotubule agent — injection formulations for Hodgkin lymphoma and germ-cell tumours.

vinca alkaloid antimicrotubule agent — injection formulations for leukaemias and lymphomas.

semi-synthetic vinca alkaloid — injection formulations for non-small-cell lung and breast cancer.